Role of remimazolam in gastrointestinal endoscopy: American Society for Gastrointestinal Endoscopy clinical practice update.

Authors

ASGE Standards of Practice Committee, Daryl Ramai, Markus W Hollmann, Sudipta Sen, Faisal Ali, Sara Ghoneim, Sydney Greenberg, Sunil Gupta, Manol Jovani, Calvin Lee, Jorge D Machicado, Jared Magee, Sultan Mahmood, Guillermo A Ortiz, Michael D Rice, Monica Saumoy, Sumit K Singla, Christopher W Teshima, Nirav C Thosani, ASGE Standards of Practice Committee Chair

Published in

Gastrointestinal endoscopy. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

This clinical practice update provides evidence-based recommendations on the use of remimazolam, a novel ultra-short-acting benzodiazepine, for procedural sedation during GI endoscopy. Remimazolam was approved by the Food and Drug Administration in July 2020 for use in procedural sedation. It offers rapid onset, short duration of action, and organ-independent metabolism, making it an alternative to traditional sedatives such as midazolam and propofol. This update synthesizes data from randomized controlled trials, meta-analyses, and real-world studies, addressing efficacy, safety, dosing, and patient selection. It aims to assist clinicians in optimizing sedation while minimizing risks, particularly in high-risk populations. Previous guidelines, such as the 2018 American Society for Gastrointestinal Endoscopy guidelines on sedation and anesthesia in GI endoscopy, focused on midazolam and propofol but did not include remimazolam. This update incorporates emerging evidence to guide the integration of remimazolam into practice.

PMID:
42848339
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.